A Multisite Open-label Trial Randomizing HIV Infected Patients on Tenofovir, Emtricitabine (or Lamivudine) and Lopinavir/Ritonavir Into Continuing the Same Regimen or Switching the Regimen to Raltegravir and Darunavir/Ritonavir.

Trial Profile

A Multisite Open-label Trial Randomizing HIV Infected Patients on Tenofovir, Emtricitabine (or Lamivudine) and Lopinavir/Ritonavir Into Continuing the Same Regimen or Switching the Regimen to Raltegravir and Darunavir/Ritonavir.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Darunavir (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms SPARE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 23 Feb 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top